Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011860 (
type 2 diabetes
)
57,723
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
AMP-activated protein kinase
(
AMPK
) is a key sensor and regulator of intracellular and whole-body energy metabolism. We have identified a thienopyridone family of
AMPK
activators. A-769662 directly stimulated partially purified rat liver
AMPK
(EC50 = 0.8 microM) and inhibited fatty acid synthesis in primary rat hepatocytes (IC50 = 3.2 microM). Short-term treatment of normal Sprague Dawley rats with A-769662 decreased liver malonyl CoA levels and the respiratory exchange ratio, VCO2/VO2, indicating an increased rate of whole-body fatty acid oxidation. Treatment of ob/ob mice with 30 mg/kg b.i.d. A-769662 decreased hepatic expression of PEPCK, G6Pase, and FAS, lowered plasma glucose by 40%, reduced body weight gain and significantly decreased both plasma and liver triglyceride levels. These results demonstrate that small molecule-mediated activation of
AMPK
in vivo is feasible and represents a promising approach for the treatment of
type 2 diabetes
and the metabolic syndrome.
...
PMID:Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. 1675 76
Insulin resistance is associated with impaired skeletal muscle oxidation capacity and reduced mitochondrial number and function. Here, we report that adiponectin signaling regulates mitochondrial bioenergetics in skeletal muscle. Individuals with a family history of
type 2 diabetes
display skeletal muscle insulin resistance and mitochondrial dysfunction; adiponectin levels strongly correlate with mtDNA content. Knockout of the adiponectin gene in mice is associated with insulin resistance and low mitochondrial content and reduced mitochondrial enzyme activity in skeletal muscle. Adiponectin treatment of human myotubes in primary culture induces mitochondrial biogenesis, palmitate oxidation, and citrate synthase activity, and reduces the production of reactive oxygen species. The inhibition of adiponectin receptor expression by siRNA, or of
AMPK
by a pharmacological agent, blunts adiponectin induction of mitochondrial function. Our findings define a skeletal muscle pathway by which adiponectin increases mitochondrial number and function and exerts antidiabetic effects.
...
PMID:Role of adiponectin in human skeletal muscle bioenergetics. 1681 34
The
AMP-activated protein kinase
(
AMPK
) is an energy-sensing enzyme that is activated by acute increases in the cellular [AMP]/[ATP] ratio. In skeletal and/or cardiac muscle,
AMPK
activity is increased by stimuli such as exercise, hypoxia, ischemia, and osmotic stress. There are many lines of evidence that increasing
AMPK
activity in skeletal muscle results in increased rates of glucose transport. Although similar to the effects of insulin to increase glucose transport in muscle, it is clear that the underlying mechanisms for
AMPK
-mediated glucose transport involve proximal signals that are distinct from that of insulin. Here, we discuss the evidence for
AMPK
regulation of glucose transport in skeletal and cardiac muscle and describe research investigating putative signaling mechanisms mediating this effect. We also discuss evidence that
AMPK
may play a role in enhancing muscle and whole body insulin sensitivity for glucose transport under conditions such as exercise, as well as the use of the
AMPK
activator AICAR to reverse insulin-resistant conditions. The identification of
AMPK
as a novel glucose transport mediator in skeletal muscle is providing important insights for the treatment and prevention of
type 2 diabetes
.
...
PMID:AMP-activated protein kinase and the regulation of glucose transport. 1682 58
AMP-activated protein kinase
(
AMPK
) is an energy sensor that regulates cellular metabolism. When activated by a deficit in nutrient status,
AMPK
stimulates glucose uptake and lipid oxidation to produce energy, while turning off energy-consuming processes including glucose and lipid production to restore energy balance.
AMPK
controls whole-body glucose homeostasis by regulating metabolism in multiple peripheral tissues, such as skeletal muscle, liver, adipose tissues, and pancreatic beta cells--key tissues in the pathogenesis of
type 2 diabetes
. By responding to diverse hormonal signals including leptin and adiponectin,
AMPK
serves as an intertissue signal integrator among peripheral tissues, as well as the hypothalamus, in the control of whole-body energy balance.
...
PMID:AMP-activated protein kinase signaling in metabolic regulation. 1682 75
The
AMP-activated protein kinase
(
AMPK
) system is a regulator of energy balance at both the cellular and whole-body levels that, once activated by low energy status, effects a switch from ATP-consuming anabolic pathways to ATP-producing catabolic pathways. It now appears to be the major target for two existing classes of drug used to treat
type 2 diabetes
, i.e., the biguanides and thiazolidinediones. However, in both cases these activate
AMPK
indirectly, and an interesting question concerns whether a drug that directly activated
AMPK
would retain the therapeutic benefits of the existing drugs while eliminating unwanted side effects.
AMPK
activators also now have potential as anticancer drugs.
...
PMID:AMP-activated protein kinase as a drug target. 1687 84
Cell dysfunction and death induced by lipid accumulation in nonadipose tissues, or lipotoxicity, may contribute to the pathogenesis of obesity and
type 2 diabetes
. However, the mechanisms leading to lipotoxic cell death are poorly understood. We recently reported that, in Chinese hamster ovary (CHO) cells and in H9c2 cardiomyoblasts, lipid overload induced by incubation with 500 muM palmitate leads to intracellular accumulation of reactive oxygen species, which subsequently induce endoplasmic reticulum (ER) stress and cell death. Here, we show that palmitate also impairs ER function through a more direct mechanism. Palmitate was rapidly incorporated into saturated phospholipid and triglyceride species in microsomal membranes of CHO cells. The resulting membrane remodeling was associated with dramatic dilatation of the ER and redistribution of protein-folding chaperones to the cytosol within 5 h, indicating compromised ER membrane integrity. Increasing beta-oxidation, through the activation of
AMP-activated protein kinase
, decreased palmitate incorporation into microsomes, decreased the escape of chaperones to the cytosol, and decreased subsequent caspase activation and cell death. Thus, palmitate rapidly increases the saturated lipid content of the ER, leading to compromised ER morphology and integrity, suggesting that impairment of the structure and function of this organelle is involved in the cellular response to fatty acid overload.
...
PMID:Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. 1696 Feb 61
AMP-activated protein kinase
(
AMPK
) is an enzyme that works as a fuel gauge which becomes activated in situations of energy consumption.
AMPK
functions to restore cellular ATP levels by modifying diverse metabolic and cellular pathways. In the skeletal muscle,
AMPK
is activated during exercise and is involved in contraction-stimulated glucose transport and fatty acid oxidation. In the heart,
AMPK
activity increases during ischaemia and functions to sustain ATP, cardiac function and myocardial viability. In the liver,
AMPK
inhibits the production of glucose, cholesterol and triglycerides and stimulates fatty acid oxidation. Recent studies have shown that
AMPK
is involved in the mechanism of action of metformin and thiazolidinediones, and the adipocytokines leptin and adiponectin. These data, along with evidence that pharmacological activation of
AMPK
in vivo improves blood glucose homeostasis, cholesterol concentrations and blood pressure in insulin-resistant rodents, make this enzyme an attractive pharmacological target for the treatment of
type 2 diabetes
, ischaemic heart disease and other metabolic diseases.
...
PMID:AMP-activated protein kinase: Role in metabolism and therapeutic implications. 1702 83
Berberine is a plant alkaloid used in traditional Chinese medicine and has been reported to have antihyperglycemic activity in
NIDDM
patients. However, the molecular basis for this action is yet to be elucidated. Here we investigate the effects and signaling pathways of berberine on L6 rat skeletal muscles. Our study demonstrates that berberine stimulates glucose uptake in a time- and dose-dependent manner. Intriguingly, berberine-stimulated glucose uptake does not vary as insulin concentration increases, and could not be blocked by the PI 3-kinase inhibitor wortmannin. Berberine only weakly stimulates the phosphorylation of Akt/PKB, a key molecule in the insulin signaling pathway, but strongly promotes the phosphorylation of
AMPK
and p38 MAPK. The effects of berberine are not a result of pro-oxidant action, but a consequence of an increased cellular AMP:ATP ratio. Moreover, berberine-stimulated glucose uptake is inhibited by the
AMPK
inhibitor Compound C and the p38 MAPK inhibitor SB202190. Inhibition of
AMPK
reduces p38 MAPK phosphorylation, suggesting that
AMPK
lies upstream of p38 MAPK. These results suggest that berberine circumvents insulin signaling pathways and stimulates glucose uptake through the AMP-
AMPK
-p38 MAPK pathway, which may account for the antihyperglycemic effects of this drug.
...
PMID:Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. 1704 64
Interleukin (IL)-6 is a pleiotropic hormone that has both proinflammatory and anti-inflammatory actions.
AMP-activated protein kinase
(
AMPK
) is a fuel-sensing enzyme that among its other actions responds to decreases in cellular energy state by enhancing processes that generate ATP and inhibiting others that consume ATP but are not acutely necessary for survival. IL-6 is synthesized and released from skeletal muscle in large amounts during exercise, and in rodents, the resultant increase in its concentration correlates temporally with increases in
AMPK
activity in multiple tissues. That IL-6 may be responsible in great measure for these increases in
AMPK
is suggested by the fact it increases
AMPK
activity both in muscle and adipose tissue in vivo and in incubated muscles and cultured adipocytes. In addition, we have found that
AMPK
activity is diminished in muscle and adipose tissue of 3-month-old IL-6 knockout (KO) mice at rest and that the absolute increases in
AMPK
activity in these tissues caused by exercise is diminished compared with control mice. Except for an impaired ability to exercise and to oxidize fatty acids, the IL-6 KO mouse appears normal at 3 months of age. On the other hand, by age 9 months, it manifests many of the abnormalities of the metabolic syndrome including obesity, dyslipidemia, and impaired glucose tolerance. This, plus the association of decreased
AMPK
activity with similar abnormalities in a number of other rodents, suggests that a decrease in
AMPK
activity may be a causal factor. Whether increases in IL-6, by virtue of their effects on
AMPK
, contribute to the reported ability of exercise to diminish the prevalence of
type 2 diabetes
, coronary heart disease, and other disorders associated with the metabolic syndrome remains to be determined.
...
PMID:Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome. 1713 Jun 44
Obesity is strongly associated with the pathogenesis of
type 2 diabetes
, hypertension, and cardiovascular disease. Levels of the hormone adiponectin are downregulated in obese individuals, and several experimental studies show that adiponectin protects against the development of various obesity-related metabolic and cardiovascular diseases. Adiponectin exhibits favorable effects on atherogenesis, endothelial function, and vascular remodeling by modulation of signaling cascades in cells of the vasculature. More recent findings have shown that adiponectin directly affects signaling in cardiac cells and is beneficial in the setting of pathological cardiac remodeling and acute cardiac injury. Several of these effects of adiponectin have been attributed to the activation of the 5'
AMP-activated protein kinase
signaling cascade and other signaling proteins. This review will discuss the epidemiological and experimental studies that have elucidated the role of adiponectin in a variety of cardiovascular diseases.
...
PMID:Adiponectin actions in the cardiovascular system. 1714 May 53
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>